Medicilon, a one-stop pharmaceutical preclinical research and development CRO, can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND approvals to initiate clinical trials. In recent years, based on the "API + formulation" one-stop CMC service platform , Medicilon has expanded from process R&D to industrial commercial production and committed to expanding from preclinical CRO to CRDMO, further strengthening our ability to collaborate with industry partners in the development of new drugs. Effective March 4 , 2024, Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon’s services in the CRDMO field, leading the...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services